IP Library Granted Patent US 11,058,617
Granted Patent B2
US 11,058,617 · App. 16/713,732 · Granted Jul 13, 2021

Methods

Inventors: Lisa Manus (Lawrenceville, NJ); Michael Stranick (Bridgewater, NJ); Donghui Wu (Bridgewater, NJ)
Assignee: Colgate-Palmolive Company
A61K8/27A61K8/362A61K8/44A61Q11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,058,617
App. No.
16/713,732
Granted
Jul 13, 2021
Kind
B2
Abstract

Provided herein are methods of treating one or more symptoms of a gastric disorder in the oral cavity of a subject in need thereof, wherein the method comprises applying to the subject's teeth an oral care composition comprising a basic amino acid in free or salt form, wherein the basic amino acid is arginine (e.g., free form arginine); zinc oxide and zinc citrate; and an orally acceptable carrier.

Claims (16)

1. A method of treating one or more symptoms of a gastric disorder in the oral cavity of a subject in need thereof, wherein the method comprises applying to the subject's teeth an oral care composition comprising:

a. a basic amino acid in free or salt form, wherein the basic amino acid is arginine in an amount from 0.1 wt % to 6.0 wt %;

b. zinc oxide and zinc citrate, wherein the zinc oxide is present in an amount from 0.75% by wt. to 1.25% by wt. and the zinc citrate is present in an amount from 0.25% by wt. to 1.0% by wt;

c. an orally acceptable carrier;

wherein the gastric disorder is gastroesophageal reflux disease (GERD); and

wherein the one or more symptoms of the gastric disorder comprise dental erosion due to loss of calcium in the subject's tooth enamel consequent to the presence of gastric acid in the oral cavity.

2. The method according to claim 1 , wherein the oral care composition inhibits or decreases the release of calcium from the subject's tooth enamel.

3. The method according to claim 2 , wherein the inhibition or decrease of the release of calcium in the subject's tooth enamel is relative to a reference standard.

4. The method according to claim 1 , wherein the oral care composition inhibits the release of calcium relative to one or more compositions that do not contain zinc.

5. The method according to claim 1 , wherein the one or more symptoms is that the subject is exposed to gastric acids in the oral cavity during sleep.

6. The method according to claim 1 , wherein the subject is at risk for dental erosion.

7. The method according to claim 6 , wherein the risk for dental erosion is selected from the group consisting of: xerostomia, tooth hypersensitivity, weakened tooth integrity, and tooth discoloration.

8. The method according to claim 1 , wherein the oral care composition comprises:

a. about 1.0% zinc oxide,

b. about 0.5% zinc citrate, and

c. about 1.5% L-arginine.

Continuity (2)
Provisional Application 62782838 · Dec 20, 2018
Related Publication 20200197271A1 · Jun 25, 2020